Inventor
DOMI ARBAN
US17 patents
⚠️ This page may combine multiple inventors who share the name “DOMI ARBAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GEOVAX INC
12 patentsUS11311612B2Apr 26, 2022
Compositions and methods for generating an immune response to treat or prevent malaria
GEOVAX INC6 citations83
US11857611B2Jan 2, 2024
Compositions and methods for generating an immune response to treat or prevent malaria
GEOVAX INC2 citations71
US11052148B2Jul 6, 2021
Compositions and methods for generating an immune response to hepatitis B virus
GEOVAX INC2 citations70
US11413341B2Aug 16, 2022
Vaccinia viral vectors encoding chimeric virus like particles
GEOVAX INC1 citations69
US11278607B2Mar 22, 2022
Compositions and methods for generating an immune response to a tumor associated antigen
GEOVAX INC2 citations69
US12329808B2Jun 17, 2025
Compositions and methods for generating an immune response to treat or prevent malaria
GEOVAX INC0 citations60
US11638750B2May 2, 2023
Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein
GEOVAX INC0 citations60
US12247214B2Mar 11, 2025
Vaccinia viral vectors encoding chimeric virus like particles
GEOVAX INC0 citations59
US12370249B2Jul 29, 2025
Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40)
GEOVAX INC0 citations58
US11896657B2Feb 13, 2024
Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus glycoprotein (GP) and matrix protein (VP40)
GEOVAX INC0 citations58
US12577589B2Mar 17, 2026
Vaccines and uses thereof to induce an immune response to SARS-CoV2
GEOVAX INC0 citations55
US11701418B2Jul 18, 2023
Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
GEOVAX INC0 citations49
INT AIDS VACCINE INITIATIVE
3 patentsUS9347065B2May 24, 2016
Methods to improve vector expression and genetic stability
INT AIDS VACCINE INITIATIVE7 citations78
US9944935B2Apr 17, 2018
Methods to improve vector expression and genetic stability
INT AIDS VACCINE INITIATIVE0 citations46
US10081796B2Sep 25, 2018
Neutralization-resistant CDV mutants and viral vectors
INT AIDS VACCINE INITIATIVE0 citations45